Our lead butyrylcholinesterase inhibitors (PE01 and PE02) selectively target butyrylcholinesterase, an enzyme similar to acetylcholinesterase. In Alzheimer's disease, butyrylcholinesterase levels increase in specific brain areas as acetylcholinesterase levels decrease. Both enzymes degrade acetylcholine, a key neurotransmitter, at synaptic gaps, affecting cognition.

Our inhibitors counter butyrylcholinesterase, enhancing acetylcholine availability, and potentially improving memory and cognition. They may also mitigate increased beta-amyloid toxicity associated with butyrylcholinesterase in amyloid plaques. Our leads boast very high potency as a butyrylcholinesterase inhibitor. They might serve multiple purposes: inhibiting butyrylcholinesterase, suppressing beta-APP production to inhibit amyloid plaque formation and potentially serving as an early diagnostic marker.